Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.35 |
| ▸ | CLK2 | P49760 | 3/20 | 0.35 |
| ▸ | CLK3 | P49761 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.34 |
| ▸ | CDK1 | P06493 | 4/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20618201 | 0.87 | GSK3B (0.40) | GSK3BRIPK1CLK2CLK3DYRK1A | |
| SCHEMBL21755111 | 0.80 | RIPK1 (0.53) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL19976237 | 0.73 | CDK8 (0.52) | GSK3BRIPK1CLK2DYRK1ABRD4 | |
| SCHEMBL21117175 | 0.71 | RIPK1 (0.48) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL22546457 | 0.71 | AXL (0.46) | GSK3BBRD4CCNB2CDK1CCNB1 | |
| SCHEMBL20252218 | 0.70 | DAO (0.38) | GSK3BCLK2CLK3DYRK1ACYP19A1 | |
| SCHEMBL15279970 | 0.67 | GSK3B (0.68) | GSK3BDYRK1ACCNB2CDK1CCNB1 | |
| SCHEMBL20622212 | 0.67 | PIK3CD (0.32) | RIPK1BRD4PIK3CD | |
| SCHEMBL24987967 | 0.66 | CCNE1 (0.38) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL6489332 | 0.66 | CCNB2 (0.61) | GSK3BRIPK1CYP19A1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | GSK3B 1579/4885RIPK1 1743/4885CLK2 4616/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | GSK3B 1579/4885RIPK1 1743/4885CLK2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.